The independent source for health policy research, polling, and news.
81 - 100 of 1,296 Results
Two senior scientists say National Institutes of Health officials advised them to remove references to mRNA vaccines in grant applications, and they fear the Trump administration will abandon a promising field of medical research.
The FDA is already limited in policing claims of health benefits by makers of supplements and herbal remedies — a $70 billion industry. Get ready for even less regulation.
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
Pain MD, which once ran as many as 20 clinics across three states, gave chronic-pain patients about 700,000 total injections near their spines, according to court documents. Last year, federal prosecutors proved at trial that the shots were medically unnecessary and part of an extensive fraud scheme.
Frustrated by spiraling drug costs, California lawmakers want to increase oversight of pharmaceutical industry intermediaries known as pharmacy benefit managers. It’s unclear whether they can persuade Gov. Gavin Newsom to get on board.
From rolling back drug pricing policies to limiting gender-affirming care, President Donald Trump signed several health-related executive orders in the first hours of his second presidency. Here’s a roundup of the changes and what they mean.
The federal government has allocated $1.15 billion to long-covid research without any new treatments yet brought to market. Patients and scientists say it’s time to push harder for breakthroughs.
As Gov. Gavin Newsom enters the second half of his final term, health care stands out as his most ambitious but glaringly incomplete initiative for California residents. The issue will likely shape his national profile for better or worse. And now, Donald Trump brings a new wrinkle.
Since 2018, readers and listeners sent KFF Health News-NPR’s “Bill of the Month” thousands of questionable bills. Our crowdsourced investigation paved the way for landmark legislation and highlighted cost-saving strategies for all patients.
Donald Trump’s first administration advanced rules forcing hospitals and insurers to reveal prices for medical services. Employers don’t want to risk backtracking during Trump’s second administration.
KFF Health News gives readers a chance to comment on a recent batch of stories.
As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the “Big Three” PBMs — or force them to change.
The outpouring of anger at health insurers following the killing of UnitedHealthcare CEO Brian Thompson continues a cycle of rage that dates back decades.
GLP-1 agonist medications such as Ozempic accounted for 10% of the North Carolina state employee health plan’s prescription drug spending, so the state is no longer covering them for weight loss alone. Still, it did decide to cover them for Medicaid patients’ weight loss. A look inside the state’s coverage calculus.
Florida sued the FDA over what it said was a “reckless delay” in approving its drug importation plan. Now, nearly a year after the FDA gave the state the green light, the program has yet to begin.
Listen to KFF Health News' Jackie Fortiér recount how a backyard snakebite led to a harrowing hospitalization — and big bills — for a San Diego family.
Though the former president has repeatedly hyped the impact of his experimental drug program, there’s no basis for his claims in government data, and medical experts say he’s exaggerating.
Health care has ebbed and surged as an election issue throughout the presidential campaign. Here are the ways some of the most consequential changes in health policies could hinge on whether Vice President Kamala Harris or former President Donald Trump wins.
With Election Day rapidly approaching, abortion is gaining traction as a voting issue, according to public opinion polls. Meanwhile, states with abortion bans are reviving the lawsuit — dismissed by the Supreme Court on a technicality this year — that could roll back the availability of the abortion pill mifepristone. Sarah Karlin-Smith of the Pink Sheet, Rachel Cohrs Zhang of Stat, and Victoria Knight of Axios join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews Tricia Neuman, senior vice president of KFF and executive director of its Program on Medicare Policy, about Medicare open enrollment and the changes to the federal program for 2025.
© 2026 KFF